World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
41009
World Ranking
15861
National Ranking
19

Krzysztof Selmaj publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Krzysztof Selmaj sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 448 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Krzysztof Selmaj D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Krzysztof Selmaj sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1994 - Prize of the Foundation for Polish Science - Nagroda Fundacji na rzecz Nauki Polskiej for his studies into new immunological mechanisms in autoimmune diseases of the nervous system, Multiple Sclerosis in particular

Overview

Krzysztof Selmaj is affiliated with the University of Warmia and Mazury in Olsztyn, Poland. Their research primarily focuses on medicine, with a significant body of work spanning pathology and forensic medicine, immunology, oncology, and neurology. The main domain of research involves the study of multiple sclerosis and related neurological disorders.

The scientist has contributed extensively to several research topics, including:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Immunotherapy and Immune Responses
  • Polyomavirus and Related Diseases
  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Fungal Plant Pathogen Control

Frequent co-authors collaborating with Krzysztof Selmaj include:

  • Hans-Peter Hartung
  • Bruce Cree
  • Eva Havrdová
  • Xavier Montalbán
  • Lawrence Steinman

They have published extensively in major venues relevant to neurological and immunological research. The most frequent publication venues are:

  • Neurology
  • Multiple Sclerosis Journal
  • Multiple Sclerosis and Related Disorders
  • Journal of Neurology
  • Frontiers in Neurology

Recent significant papers authored or co-authored by Krzysztof Selmaj encompass the following:

  • "Ofatumumab versus Teriflunomide in Multiple Sclerosis", 2020, New England Journal of Medicine
  • "Myelin-oligodendrocyte glycoprotein antibody-associated disease", 2021, The Lancet Neurology
  • "Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis", 2022, New England Journal of Medicine
  • "Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study", 2020, CNS Drugs
  • "Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study", 2021, Multiple Sclerosis Journal

Krzysztof Selmaj has been recognized with the Prize of the Foundation for Polish Science (Nagroda Fundacji na rzecz Nauki Polskiej) in 1994 for research into new immunological mechanisms in autoimmune diseases of the nervous system, specifically multiple sclerosis.

Best Publications

  • A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

    Ludwig Kappos;Ernst Wilhelm Radue;Paul O'Connor;Chris Polman

  • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer

  • Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

    Krzysztof W. Selmaj;Cedric S. Raine

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

    R. H.S.R. Roxburgh;S. R. Seaman;T. Masterman;A. E. Hensiek

  • Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

    K Selmaj;C S Raine;B Cannella;C F Brosnan

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

    Camms Trial Investigators;Alasdair J Coles;D Alastair S Compston;Krzysztof W Selmaj

  • Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor.

    K W Selmaj;M Farooq;W T Norton;C S Raine

  • Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Stephen L. Hauser;Amit Bar-Or;Jeffrey A. Cohen;Giancarlo Comi

  • Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin.

    K Selmaj;C S Raine;M Farooq;W T Norton

  • Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.

    K. Selmaj;C. S. Raine;A. H. Cross

  • Myelin-oligodendrocyte glycoprotein antibody-associated disease.

    Romain Marignier;Romain Marignier;Yael Hacohen;Alvaro Cobo-Calvo;Anne Katrin Pröbstel

  • Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis.

    Krzysztof Selmaj;Celia F. Brosnan;Cedric S. Raine

  • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

    G Giancarlo Comi;A. Pulizzi;Marco Rovaris;O. Abramsky

  • Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

    Ralf Gold;Gavin Giovannoni;Krzysztof Selmaj;Eva Havrdova

Frequent Co-Authors

Eva Havrdova
Eva Havrdova Charles University
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Amit Bar-Or
Amit Bar-Or University of Pennsylvania
Ralf Gold
Ralf Gold Ruhr University Bochum
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Cedric S. Raine
Cedric S. Raine Albert Einstein College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers but seeking alternative routes to becoming a doctor, several online degree options can open doors to healthcare professions. One increasingly popular choice is nursing, a field with high demand and diverse opportunities for advancement.

Students looking for the fastest entry into nursing may consider the cheapest online accelerated bsn programs. These programs are ideal for those who already hold a non-nursing bachelor’s degree and want to transition quickly into the nursing workforce.

For registered nurses aiming to expand their qualifications, rn to bsn online programs offer a flexible path to a bachelor’s degree, improving career prospects and earning potential. Meanwhile, non-nurses with a bachelor’s degree can explore entry level msn programs online to become advanced practice nurses directly.

Nurses interested in leadership or research roles might pursue a phd in nursing. This high-level degree prepares graduates for positions in academia, policy, or advanced clinical practice. These online pathways offer flexible and affordable options for entering or advancing within the healthcare field.

Best Scientists Citing Krzysztof Selmaj

Trending Scientists

Recently Published Articles